
Insider and congress filings
Moderna, Inc. (MRNA)
NASDAQ · Healthcare · 39 insider transactions · 58 congress trades · last filed 10 days agoS&P 500Nasdaq 100
About Moderna, Inc.
from the company's filings and listing, as of Oct 20, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Stéphane Bancel
- Employees
- 4,700
- Listed since
- Dec 7, 2018
- Market value
- $90.6B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$7.96
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 6, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 31, 2026 | -$1.97 | -$2.03 | $145.0M | $102.9M | EPS beat, GAAPRevenue beat |
| Q1 FY2026reported May 1, 2026 | -$3.40 | -$4.45 | $389.0M | $236.4M | EPS beat, GAAPRevenue beat |
| Q4 FY2025reported Feb 13, 2026 | -$2.11 | -$2.54 | $678.0M | $635.2M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$0.51 | -$1.87 | $1.0B | $920.9M | EPS beat, GAAPRevenue beat |
| Q2 FY2025reported Aug 1, 2025 | -$2.13 | -$2.99 | $142.0M | $893.3M | EPS beat, GAAPRevenue miss |
| Q1 FY2025reported May 1, 2025 | -$2.52 | -$2.92 | $107.0M | $116.7M | EPS beat, GAAPRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Mar 16, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Stéphane BancelChief Executive Officer | $1.7M | $6.9M | $11.4M | $19.9M |
| Stephen Hoge, M.D.President | $1.3M | $9.2M | $7.6M | $18.1M |
| James MockChief Financial Officer | $852K | $2.5M | $2.6M | $5.9M |
| Shannon Thyme KlingerChief Legal Officer and Corporate Secretary | $852K | $2.1M | $2.4M | $5.4M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $3.6B | 51,859,891 | +13.5% | 13.10% |
| BlackRock, Inc. | $2.1B | 30,599,409 | +3.3% | 7.73% |
| Vanguard Capital Management LLC | $1.6B | 23,208,792 | +1.5% | 5.86% |
| Capital World Investors | $1.6B | 22,276,996 | +19.1% | 5.63% |
| Baillie Gifford & Co | $1.3B | 18,206,778 | -8.9% | 4.60% |
| State Street Corp | $1.1B | 15,726,193 | +5.8% | 3.98% |
| Vanguard Portfolio Management LLC | $1.1B | 15,581,313 | -0.2% | 3.93% |
| Geode Capital Management, LLC | $678.8M | 9,710,335 | +2.9% | 2.45% |
| Morgan Stanley | $668.0M | 9,538,094 | +12.6% | 2.41% |
| Theleme Partners LLP | $564.3M | 8,057,571 | +0.1% | 2.03% |
| Two Sigma Investments, LP | $503.8M | 7,193,530 | -20.8% | 1.82% |
| Invesco Ltd. | $404.8M | 5,780,299 | +20.8% | 1.46% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Open-market insider trades
7 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Stephen HogePresident | Sold · scheduled | 39,145 | $220.72 | $8.6M | Oct 15, 2026filed Oct 16, 2026 | 1d |
| Stephen HogePresident | Sold · scheduled · 2 lines | 39,224 | $213.48 | $8.4M | Oct 14, 2026filed Oct 16, 2026 | 2d |
| Stephen HogePresident | Sold · scheduled | 40,281 | $146.07 | $5.9M | Sep 15, 2026filed Sep 16, 2026 | 1d |
| Stephen HogePresident | Sold · scheduled | 40,294 | $144.13 | $5.8M | Sep 14, 2026filed Sep 16, 2026 | 2d |
| James M. MockChief Financial Officer | Sold · scheduled · 2 lines | 34,836 | $134.49 | $4.7M | Sep 10, 2026filed Sep 14, 2026 | 2d |
| Stephane BancelChief Executive Officer | Sold · scheduled · 4 lines | 499,246 | $57.52 | $28.7M | Aug 5, 2026filed Aug 7, 2026 | 2d |
| Stephen HogePresident | Sold · scheduled | 53,336 | $67.60 | $3.6M | Jul 15, 2026filed Jul 16, 2026 | 1d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (19)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Stephen HogePresident | Option exercise | 76,452 | Oct 15, 2026 |
| Stephen HogePresident | Option exercise | 76,453 | Oct 14, 2026 |
| James M. MockChief Financial Officer | Tax withholding | 704 | Oct 5, 2026 |
| James M. MockChief Financial Officer | Option exercise | 1,454 | Oct 5, 2026 |
| Stephen HogePresident | Option exercise | 76,452 | Sep 15, 2026 |
| Stephen HogePresident | Option exercise | 76,453 | Sep 14, 2026 |
| James M. MockChief Financial Officer | Option exercise | 19,836 | Sep 10, 2026 |
| James M. MockChief Financial Officer | Tax withholding | 5,704 | Sep 4, 2026 |
| James M. MockChief Financial Officer | Option exercise | 11,797 | Sep 4, 2026 |
| Shannon Thyme KlingerChief Legal Officer | Tax withholding | 5,704 | Sep 4, 2026 |
| Shannon Thyme KlingerChief Legal Officer | Option exercise | 11,797 | Sep 4, 2026 |
| Stephane BancelChief Executive Officer | Option exercise | 317,397 | Aug 6, 2026 |
| Stephane BancelChief Executive Officer | Option exercise | 998,492 | Aug 5, 2026 |
| Stephen HogePresident | Option exercise | 53,336 | Jul 15, 2026 |
| Michael R. McDonnellDirector | Stock award | 14,766 | Jul 8, 2026 |
| Soria Ester BanqueChief Commercial Officer | Stock award | 57,022 | Jul 5, 2026 |
| James M. MockChief Financial Officer | Tax withholding | 703 | Jul 2, 2026 |
| James M. MockChief Financial Officer | Option exercise | 1,452 | Jul 2, 2026 |
| Stephen HogePresident | Option exercise | 53,336 | Jun 15, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in MRNA
20 disclosures of 58 on record · median 22d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Maria Elvira Salazar | Stock | Sale | $1,001 - $15,000 | +2.7%After the saleS&P 500 -1.2% · +3.9 pts vs S&P 500 | Sep 24, 2026 | Oct 7, 2026 | 13d |
| Maria Elvira Salazar | Stock | Purchase | $1,001 - $15,000 | +14.8%S&P 500 -1.2% · +15.9 pts vs S&P 500 | Aug 19, 2026 | Sep 9, 2026 | 21d |
| Maria Elvira Salazar | Stock | Sale | $1,001 - $15,000 | +14.8%After the saleS&P 500 -1.2% · +15.9 pts vs S&P 500 | Aug 19, 2026 | Sep 9, 2026 | 21d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +262.9%After the saleS&P 500 +0.3% · +262.6 pts vs S&P 500 | Aug 3, 2026 | Sep 4, 2026 | 32d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +44.1%S&P 500 -0.5% · +44.5 pts vs S&P 500 | Aug 24, 2026 | Sep 4, 2026 | 11d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +185.7%S&P 500 +1.7% · +184.0 pts vs S&P 500 | Jun 30, 2026 | Jul 6, 2026 | 6d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +341.0%After the saleS&P 500 +5.4% · +335.6 pts vs S&P 500 | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +308.0%After the saleS&P 500 +2.8% · +305.2 pts vs S&P 500 | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +294.8%S&P 500 +10.8% · +284.1 pts vs S&P 500 | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +310.8%S&P 500 +10.2% · +300.6 pts vs S&P 500 | Jan 23, 2026 | Feb 6, 2026 | 14d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +709.1%After the saleS&P 500 +17.8% · +691.4 pts vs S&P 500 | Aug 26, 2025 | Sep 9, 2025 | 14d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +485.9%S&P 500 +19.3% · +466.7 pts vs S&P 500 | Jul 25, 2025 | Aug 7, 2025 | 13d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +658.2%After the saleS&P 500 +27.8% · +630.5 pts vs S&P 500 | May 19, 2025 | Jun 10, 2025 | 22d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +716.7%After the saleS&P 500 +44.9% · +671.8 pts vs S&P 500 | Apr 10, 2025 | May 12, 2025 | 32d |
| Robert Bresnahan | Stock | Sale | $1,001 - $15,000 | +712.1%After the saleS&P 500 +53.0% · +659.1 pts vs S&P 500 | Apr 8, 2025 | May 8, 2025 | 30d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +501.3%S&P 500 +27.9% · +473.4 pts vs S&P 500 | Feb 25, 2025 | Mar 27, 2025 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +457.4%S&P 500 +23.9% · +433.5 pts vs S&P 500 | Feb 19, 2025 | Mar 6, 2025 | 15d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +501.3%S&P 500 +27.9% · +473.4 pts vs S&P 500 | Feb 25, 2025 | Mar 6, 2025 | 9d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +475.5%After the saleS&P 500 +28.2% · +447.3 pts vs S&P 500 | Jan 15, 2025 | Feb 12, 2025 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +246.6%S&P 500 +30.1% · +216.5 pts vs S&P 500 | Oct 14, 2024 | Nov 8, 2024 | 25d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in MRNA, filterable by party, chamber, type and account.
Members of Congress reporting a position
1 member · estimate, as of Oct 19, 20261 member reports a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Jasmine Crockett | Democrat · House | $50,001 - $100,000 | 77.6% |
Estimate, as of Oct 19, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling MRNA?
Across the 7 most recent open-market filings shown here, 0 were purchases and 7 were sales. 7 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded MRNA?
Maria Elvira Salazar, Ro Khanna, Robert Bresnahan and Julie Johnson disclosed MRNA transactions in the filings shown here.
Which members of Congress hold MRNA?
1 member of Congress reports a position in MRNA in the estimate we hold as of Oct 19, 2026. The estimated position belongs to Jasmine Crockett. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is MRNA in the S&P 500 or the Nasdaq 100?
Moderna, Inc. is a current member of the S&P 500 and Nasdaq 100, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.
How quickly are MRNA trades disclosed?
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 22 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
